Inozyme Pharma Inc. is on a mission to treat two ultra-rare and often fatal mineralization disorders that currently have no approved options with its lead enzyme therapy asset that has the potential to be a ‘pipeline in a product.’
Inozyme Targets Underserved Mineralization Disorders Market With First-In-Class Enzyme Therapy
Emerging Company Profile: Fresh from a $73m follow-on offering last year, the US biotech is readying its lead asset for a pivotal trial in ultra-rare but debilitating mineralization disorders that affect infants and children.
More from Emerging Company Profiles
• By
Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.
• By
Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.
• By
Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.
• By
Emerging Company Profile: The Maryland-based biotech is working on a functional cure for type 1 diabetes that is similar to Vertex’s VX-880 – but with some key differences.
More from Start-Ups & SMEs
• By
The Biovelocita II fund is supported by the likes of Amgen, Bristol Myers Squibb and Pfizer
• By
CEO Adam Steensberg has led a major change in fortunes for the Danish biotech since March 2022.
• By
The Singapore and Seattle-based biotech is joining the race to bring a ‘double whammy’ antibody-drug conjugate to patients.